Page last updated: 2024-12-05
hexapropymate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
hexapropymate: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9661 |
CHEMBL ID | 2104292 |
CHEBI ID | 134823 |
SCHEMBL ID | 1550506 |
MeSH ID | M0041485 |
Synonyms (55)
Synonym |
---|
modirax |
nsc-169094 |
hexapropymate |
lunamin |
l2103 |
carbamic acid, 1-(2-propynyl)cyclohexyl ester |
1-(2-propynyl)cyclohexanol carbamate |
propynylcyclohexanol carbamate |
nsc169094 |
1-(2-propynyl)cyclohexyl carbamate |
wln: l6tj aovz a2uu1 |
l 2103 |
merinax |
esapropimato |
1-carbamoyloxy-1-(2-propynyl)cyclohexane |
358-52-1 |
1-(2-propynyl)-1-cyclohexanol carbamate |
hexopropynate |
lf 62 |
l-2103 , |
hexapropimato [inn-spanish] |
brn 3253991 |
hexapropymate [inn:ban:dcf] |
carbamate du propinylcyclohexanol [french] |
nsc 169094 |
cyclohexanol, 1-(2-propynyl)-, carbamate |
hexapropymatum [inn-latin] |
einecs 206-618-9 |
merinax (tn) |
D07331 |
hexapropymate (inn) |
CHEBI:134823 |
(1-prop-2-ynylcyclohexyl) carbamate |
hexapropimato |
unii-0j9rn2prj7 |
0j9rn2prj7 , |
hexapropymatum |
carbamate du propinylcyclohexanol |
4-06-00-00362 (beilstein handbook reference) |
AKOS006240457 |
CHEMBL2104292 |
FT-0603383 |
hexapropymate [who-dd] |
hexapropymate [inn] |
hexapropymate [mi] |
hexapropymate [mart.] |
SCHEMBL1550506 |
DTXSID00189329 |
1-(prop-2-yn-1-yl)cyclohexyl carbamate |
1-(prop-2-ynyl)cyclohexyl carbamate |
Z995241878 |
DB13662 |
Q1036070 |
lunamin; l2103; nsc 169094 |
EN300-1266505 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
carbamate ester | Any ester of carbamic acid or its N-substituted derivatives. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (20.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |